Infectious Disease Research Institute CEO and leadership

As Chief Science Officer at the Infectious Disease Research Institution, Danis focusing on developing lower cost vaccines, diagnostics and therapeutics for infectious disease threats worldwide. Prior to joining IDRI, Dr. Stinchcomb was President of Global H, LLC, an infectious disease consulting company, and was co-founder and Chief Executive Officer of Inviragen, Inc. Under his leadership, Inviragen grew from a start-up to a global clinical stage company. Inviragen advanced vaccines for dengue fever and hand, foot and mouth disease from research to proof-of-concept human clinical trials and developed several vaccine candidates through advanced preclinical testing. Dr. Stinchcomb completed numerous partnerships and collaborations, executed a merger with an Asian vaccine company, and raised over $30 million in grants and contracts and over $30 million in equity financing. Inviragen was acquired by Takeda Pharmaceuticals in 2013. Prior to co-founding Inviragen, Dr. Stinchcomb held senior scientific management positions at Heska Corp., Ribozyme Pharmaceuticals, Inc., and Synergen, Inc. He started his career as an Assistant and Associate Professor in Cellular and Developmental Biology at Harvard University and post-doctoral fellow at University of Colorado. Dr. Stinchcomb holds a PhD from Stanford University and BA from Harvard College.

Specialties: Establishing global collaborations and partnerships and managing product research, development, and regulatory approvals for novel vaccines. Broad experience in biotechnology including vaccines, protein therapeutics, ribozyme and gene therapy, diagnostics and pharmaceuticals.